Key facts
- MB Therapeutics’s last known valuation is $8.7M (Feb 2025).
- It has raised $2.7M.
- Notable investors include Angels Santé, Banque Publique d'Investissement, Beprep, Business & Innovation Center, Calyseed — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for MB Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for MB Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MB Therapeutics
Operator of a pharmaceutical company intended to provide personalized medicine through healthcare three-D printing. The company offers patient-centric system for developing and producing customized medicines as well as evaluation services and specializes in customizing medication dosage, forms, and combining multiple active ingredients into a single unit, enabling healthcare professionals to enhance treatment precision and improving patient adherence.
- Sector
- Healthcare
- HQ
- Montpellier, France
- Founded
- 2023
- Employees
- 10
- Website
- mb-therapeutics.com/
- Ownership
- Privately Held (backing)
MB Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MB Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MB Therapeutics in its N-PORT filings yet. We sweep new filings monthly.